Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)70099-x ◽

2015 ◽

Vol 15 (6) ◽

pp. 645-653 ◽

Cited By ~ 255

Author(s):

Masashi Mizokami ◽

Osamu Yokosuka ◽

Tetsuo Takehara ◽

Naoya Sakamoto ◽

Masaaki Korenaga ◽

...

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

Hepatology International ◽

10.1007/s12072-016-9726-5 ◽

2016 ◽

Vol 10 (6) ◽

pp. 947-955 ◽

Cited By ~ 14

Author(s):

Young-Suk Lim ◽

Sang Hoon Ahn ◽

Kwan Sik Lee ◽

Seung Woon Paik ◽

Youn-Jae Lee ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Combination Tablet ◽

Korean Patients ◽

Phase Iiib ◽

Treatment Naïve ◽

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

Gastroenterology ◽

10.1016/s0016-5085(14)63284-4 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-903 ◽

Cited By ~ 1

Author(s):

Ira M. Jacobson ◽

Patrick Marcellin ◽

Alessandra Mangia ◽

Paul Y. Kwo ◽

Graham Foster ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Phase 3 ◽

Treatment Naïve ◽

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

The Lancet ◽

10.1016/s0140-6736(13)62121-2 ◽

2014 ◽

Vol 383 (9916) ◽

pp. 515-523 ◽

Cited By ~ 382

Author(s):

Eric Lawitz ◽

Fred F Poordad ◽

Phillip S Pang ◽

Robert H Hyland ◽

Xiao Ding ◽

...

Keyword(s):

Fixed Dose ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Faculty Opinions recommendation of Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718170953.793488463 ◽

2013 ◽

Author(s):

Doug Dieterich ◽

Kian Bichoupan

Keyword(s):

Fixed Dose ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Faculty Opinions recommendation of Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718170953.793487776 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Fixed Dose ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(14)61459-8 ◽

2014 ◽

Vol 60 (1) ◽

pp. S523-S524 ◽

Cited By ~ 3

Author(s):

A. Mangia ◽

P. Marcellin ◽

P. Kwo ◽

G.R. Foster ◽

M. Buti ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Phase 3 ◽

Treatment Naïve ◽

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

Liver International ◽

10.1111/liv.14502 ◽

2020 ◽

Vol 40 (8) ◽

pp. 1853-1859 ◽

Cited By ~ 4

Author(s):

Armand Abergel ◽

Tarik Asselah ◽

Arianne Mallat ◽

Brigitte Chanteranne ◽

Frederic Faure ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Treatment Naïve ◽

Dose Combination ◽

Severe Fibrosis

All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study

Zeitschrift für Gastroenterologie ◽

10.1055/s-0034-1385996 ◽

2014 ◽

Vol 52 (08) ◽

Author(s):

P Buggisch ◽

T Göser ◽

AW Lohse ◽

T Berg ◽

P Galle ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Phase 3 ◽

Treatment Naïve ◽

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

10.26226/morressier.5aeaf2d35800a00019097f85 ◽

2018 ◽

Author(s):

Christian Wisskirchen ◽

Hans-Jürgen Stellbrink

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination ◽

Hiv 1